Amedeo Smart

Free Medical Literature Service

 

Amedeo

Sexually Transmitted Diseases
  Free Subscription

Articles published in
Int J Cancer
    June 2026
  1. SCHROLL JB, Bonde J, Lynge E, Waldstrom M, et al
    Health care policy trial of primary human papillomavirus-based cervical screening in Denmark: Comparison of three triage algorithms.
    Int J Cancer. 2026;158:3197-3207.
    >> Share

    May 2026
  2. VANI NV, Madhanagopal R, Subramanian MJ, Sundersingh S, et al
    Prevalence, incidence, and dynamics of oral human papillomavirus infection among healthy individuals-A molecular epidemiology field study from India.
    Int J Cancer. 2026;158:2602-2612.
    >> Share

  3. ELFSTROM KM, Hortlund M, Ohman D, Dillner J, et al
    Cancer detection using human papillomavirus self-sampling targeting long-term non-attenders in an organized cervical screening program.
    Int J Cancer. 2026;158:2729-2735.
    >> Share

  4. ARMAROLI P, Zappa M, Giorgi Rossi P, Carozzi FM, et al
    Population-Based First Estimates of the Effect of HPV Vaccination in Three Italian Areas Covered by Organised Cervical Screening.
    Int J Cancer. 2026 May 5. doi: 10.1002/ijc.70536.
    >> Share

  5. STAERK MG, Munk C, Stilling C, Elversang J, et al
    Prevalence and time trends of human papillomavirus in penile cancer over 26 years-A comprehensive study of 1040 penile cancer cases from Denmark.
    Int J Cancer. 2026;158:2466-2475.
    >> Share

    April 2026
  6. TIMM S, Skjoth F, Hansen TF, Jensen LH, et al
    HPV-Related Cancers in Solid Organ Transplant Recipients: A Nationwide Danish Cohort Study.
    Int J Cancer. 2026 Apr 28. doi: 10.1002/ijc.70529.
    >> Share

  7. BEAUSSIRE-TROUVAY L, Obongo-Anga FR, Leveque E, Berghian A, et al
    Peri-Operative Detection of Circulating Tumor DNA Using a Customized NGS Tumor-Informed Assay in Patients With HPV-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Int J Cancer. 2026 Apr 10. doi: 10.1002/ijc.70478.
    >> Share

  8. JAKOBSEN KK, Rehman U, Gronhoj C, Lau ZJ, et al
    Awareness of Human Papillomavirus (HPV), Increasing Rates of Oropharyngeal Cancer, and Estimated Economic Burden in Denmark.
    Int J Cancer. 2026 Apr 7. doi: 10.1002/ijc.70477.
    >> Share

  9. MATAS I, Torne A, Saco A, Marti C, et al
    Risk stratification and anal cancer screening in immunocompetent women with genital HPV: Value of multicentric HSIL and performance of HPV-based screening.
    Int J Cancer. 2026 Apr 7. doi: 10.1002/ijc.70455.
    >> Share

    March 2026
  10. MENESES-LEON J, Rivera-Paredez B, Hernandez-Salazar S, Torres-Ibarra L, et al
    Extended HPV typing as an efficient alternative within HPV-based screening programs.
    Int J Cancer. 2026 Mar 28. doi: 10.1002/ijc.70428.
    >> Share

  11. LI R, Shayan G, Zhao Y, Zhang S, et al
    Trends and epidemiology of human papillomavirus-related oropharyngeal cancer in Chinese populations from 2010 to 2024.
    Int J Cancer. 2026;158:1564-1576.
    >> Share

  12. CUI J, Mukherjee A, Patel PG, Junkins A, et al
    Sex and organ-specific risk and temporal trends of human papillomavirus-associated anogenital cancer among solid organ transplant recipients in the United States.
    Int J Cancer. 2026;158:1507-1516.
    >> Share

  13. YAKSICH L, Hartel G, Panizza BJ, Whiteman DC, et al
    Prevalence and distribution of HPV types in Australian patients with oropharyngeal cancer over time.
    Int J Cancer. 2026 Mar 7. doi: 10.1002/ijc.70432.
    >> Share

  14. QURESHI HM, Hughes T, Franco EL, Fiest KM, et al
    Risk of cancer among individuals with a history of bacterial sexually transmitted infections: A population-based study in Alberta, Canada.
    Int J Cancer. 2026;158:1383-1395.
    >> Share

    February 2026
  15. VAHTERISTO M, Heinavaara S, Dillner J, Kalliala I, et al
    Long-term human papillomavirus genotype-specific risk of cervical high-grade intraepithelial lesion and cancer-By age group and triage cytology.
    Int J Cancer. 2026;158:931-941.
    >> Share

  16. STANKIEWICZ KARITA HC, Magaret AS, Doody DR, Schouten JT, et al
    Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): A randomized, double-blind, placebo-controlled trial.
    Int J Cancer. 2026 Feb 13. doi: 10.1002/ijc.70366.
    >> Share

  17. RASMUSSEN RMW, Munk C, Kjaer SK
    Is the beneficial effect of multi-cohort HPV vaccination on cervical cancer and precancerous lesions seen across all educational levels?
    Int J Cancer. 2026 Feb 6. doi: 10.1002/ijc.70360.
    >> Share

    January 2026
  18. KROON KR, Bogaards JA, Berkhof J
    Cost-effectiveness analysis of human papillomavirus (HPV) genotyping strategies for management of HPV-positive women in cervical cancer screening.
    Int J Cancer. 2026 Jan 28. doi: 10.1002/ijc.70344.
    >> Share

  19. LEHTINEN M, Lipsitch M, Pimenoff VN, Sundstrom K, et al
    Predicting optimal impact interventions in the post-HPV vaccination world.
    Int J Cancer. 2026 Jan 19. doi: 10.1002/ijc.70297.
    >> Share

  20. DUBE MANDISHORA RS, Goncalves MG, Fan W, Sirak B, et al
    Sequential HPV16 variant infections in the genital epithelium and anal canal of men.
    Int J Cancer. 2026;158:33-38.
    >> Share

    December 2025
  21. TSEGAYE AT, Mashele SA, Shing JZ, Mwansa-Kambafwile J, et al
    Race-specific temporal trends of HPV-related cancers in South Africa: An analysis of the South African National Cancer Registry, 2011-2022.
    Int J Cancer. 2025 Dec 31. doi: 10.1002/ijc.70323.
    >> Share

  22. HU Y, Liu Y, Guo W, Hong Z, et al
    Efficacy and safety of 5-aminolevulinic acid-based photodynamic therapy for cervical low-grade squamous intraepithelial lesions with HPV infections.
    Int J Cancer. 2025 Dec 8. doi: 10.1002/ijc.70273.
    >> Share

    November 2025
  23. ORTEGA LLOBET M, Gray P, Baussano I, Elfstrom KM, et al
    Controlled trial of cervical cancer screening frequency among human-papillomavirus-vaccinated women.
    Int J Cancer. 2025 Nov 7. doi: 10.1002/ijc.70229.
    >> Share

  24. PALMER TJ, Kavanagh K, Cuschieri K, Cameron RL, et al
    Sustained impact of bivalent HPV immunisation on CIN incidence over two rounds of cervical screening.
    Int J Cancer. 2025 Nov 3. doi: 10.1002/ijc.70183.
    >> Share

    October 2025
  25. NASMAN T, Birgersson M, Marklund L, Nasman A, et al
    Spatial evidence for carcinoma in situ (CIS) as an entity in human papillomavirus (HPV)-associated tonsillar squamous cell carcinoma (TSCC).
    Int J Cancer. 2025 Oct 23. doi: 10.1002/ijc.70207.
    >> Share

  26. CHINULA L, Chagomerana MB, Mkochi T, Msowoya L, et al
    Single visit screen-triage-treat strategy using GeneXpert-based HPV testing of self-collected cervicovaginal samples and thermal ablation treatment for cervical cancer prevention among women in Lilongwe, Malawi.
    Int J Cancer. 2025 Oct 16. doi: 10.1002/ijc.70177.
    >> Share

    September 2025
  27. LEVY B, Schwarz N, Magen Z, Vaknin Z, et al
    Comment addressing the 2025 Zero Draft: A global call for HPV elimination.
    Int J Cancer. 2025 Sep 20. doi: 10.1002/ijc.70174.
    >> Share

  28. KOESTLER AJ, Nelson CW, Yeager M, Chen Z, et al
    Whole-genome sequencing of 1,083 HPV45 cases and controls identifies genetic variants associated with glandular cervical lesions.
    Int J Cancer. 2025;157:1130-1141.
    >> Share

  29. TOTA JE, Shing JZ, Roberts JN, Anderson EM, et al
    Epidemiological approaches to evaluate clinical unmasking of HPV-associated cervical lesions in the HPV vaccination era.
    Int J Cancer. 2025 Sep 15. doi: 10.1002/ijc.70119.
    >> Share

  30. ANDERSEN K, Bonde J, Waldstrom M, Jakobsen MV, et al
    Evaluation of targeted next-generation sequencing for detection of HPV genotypes and sublineages in cervical liquid-based cytology SurePath samples from the Danish screening program.
    Int J Cancer. 2025 Sep 11. doi: 10.1002/ijc.70148.
    >> Share

  31. LIU H, Zou Z, Zhang L
    Reply to 'Comments on "HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis"'.
    Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70129.
    >> Share

  32. LIU Z, Tong X
    Comments on "HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis".
    Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70130.
    >> Share

  33. AMURE MT, Madathil SA, Laprise C, Rousseau MC, et al
    Oral co-infection with multiple alpha-human papillomavirus and head and neck cancer risk.
    Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70124.
    >> Share

    August 2025
  34. FENG X, Patel EU, Kigozi G, Gravitt PE, et al
    Longitudinal patterns of penile human papillomavirus detection among Ugandan men: A prospective sampling study.
    Int J Cancer. 2025 Aug 25. doi: 10.1002/ijc.70107.
    >> Share

  35. HAAS CB, Ocampo R, Liu D, Zuniga M, et al
    Design and initial findings of a natural history study of anal HPV and associated lesions among young adult women in Costa Rica.
    Int J Cancer. 2025 Aug 15. doi: 10.1002/ijc.70082.
    >> Share

  36. NASMAN A, Birgersson M, Nasman T, Jortso E, et al
    Age and tumour presentations differ between HPV type 16 positive and other high-risk HPV type-positive oropharyngeal squamous cell carcinomas in a Swedish cohort of 2000-2022.
    Int J Cancer. 2025 Aug 15. doi: 10.1002/ijc.70087.
    >> Share

    July 2025
  37. BJORGE T, Stoer NC, Hverven SK, Nygard M, et al
    Risk of high-grade cervical lesions in the second round of primary human papillomavirus testing in CervicalScreen Norway: A population-based cohort study.
    Int J Cancer. 2025;157:251-259.
    >> Share

    June 2025
  38. JENKINS M, Saidu R, Boa R, Mbatani N, et al
    Performance of thermoablation among women treated for high-risk human papillomavirus in a screen-and-treat program in South Africa.
    Int J Cancer. 2025 Jun 6. doi: 10.1002/ijc.35519.
    >> Share

    May 2025
  39. KJAER SK, Frederiksen K, Rasmussen CL, Thomsen LT, et al
    Prognostic impact of p16 and high-risk HPV DNA in ~1300 patients with vulvar cancer.
    Int J Cancer. 2025 May 30. doi: 10.1002/ijc.35501.
    >> Share

  40. DAMGAARD R, Jenkins D, Stoler MH, van de Sandt M, et al
    p16(INK4a) and HPV E4 immunohistochemistry for the prediction of regression of cervical intraepithelial neoplasia grade 2-A historical cohort study.
    Int J Cancer. 2025 May 5. doi: 10.1002/ijc.35469.
    >> Share

    April 2025
  41. WEI Y, Gu L, Zhang Y, Yang Q, et al
    Efficacy of ALA-PDT in treating cervical low-grade squamous intraepithelial lesions with high-risk HPV patients: A multicentre randomized controlled trial.
    Int J Cancer. 2025 Apr 23. doi: 10.1002/ijc.35450.
    >> Share

    February 2025
  42. KEBEDE HB, Mekuria S, Asegid N, Forslund O, et al
    High-risk human papillomavirus genotypes in previously unscreened reproductive-age women in Ethiopia: A community-based cohort study.
    Int J Cancer. 2025 Feb 14. doi: 10.1002/ijc.35335.
    >> Share

  43. LEHTINEN M, van Damme P, Beddows S, Pinto LA, et al
    Scientific approaches to defining HPV vaccine-induced protective immunity.
    Int J Cancer. 2025 Feb 13. doi: 10.1002/ijc.35345.
    >> Share

  44. RUNELLO F, Jary A, Duin S, Kim Y, et al
    DNA methylation and copy number alterations in the progression of HPV-associated high-grade vulvar intraepithelial lesion.
    Int J Cancer. 2025 Feb 12. doi: 10.1002/ijc.35366.
    >> Share

  45. HARPER DM, Paczos T, Ridder R, Huh WK, et al
    p16/ki-67 dual stain triage of individuals positive for HPV to detect cervical precancerous lesions.
    Int J Cancer. 2025 Feb 4. doi: 10.1002/ijc.35353.
    >> Share

  46. JIN F, Poynten IM, Hillman RJ, Law C, et al
    Does use of anal cytology as a triage test improve the performance of high-risk human papillomavirus screening in gay and bisexual men for anal cancer prevention?
    Int J Cancer. 2025;156:575-586.
    >> Share

    December 2024
  47. VERHOEF L, Bleeker MCG, Polman N, Kroon KR, et al
    Colposcopy referrals and CIN3 detection after triage by host cell DNA methylation and/or HPV genotyping in HPV positive women with low-grade cytology from a population-based Dutch primary HPV screening trial.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35289.
    >> Share

  48. JHAWAR SR, Haring C, Pan X, Ma J, et al
    Impact of circulating tumor human papillomavirus DNA kinetics on disease outcomes in HPV-associated oropharyngeal cancer.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35291.
    >> Share

  49. TUNG HJ, Wang YC, Lin CY, Liao MJ, et al
    Human papillomavirus prevalence, genotype distribution, and prognostic factors of vaginal cancer.
    Int J Cancer. 2024;155:1996-2008.
    >> Share

    November 2024
  50. PEDERSEN BT, Sonne SB, Pedersen H, Andreasen EK, et al
    Participation and relative cost of attendance by direct-mail compared to opt-in invitation strategy for HPV self-sampling targeting cervical screening non-attenders: A large-scale, randomized, pragmatic study.
    Int J Cancer. 2024 Nov 23. doi: 10.1002/ijc.35263.
    >> Share

  51. LIU H, Zou M, Shen M, Kamarulzaman A, et al
    HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis.
    Int J Cancer. 2024 Nov 17. doi: 10.1002/ijc.35242.
    >> Share

  52. KARIMI A, Mohebbi E, Mckay-Chopin S, Hadji M, et al
    Association of opium use and tobacco smoking with alpha-, beta-, and gamma-human papillomavirus oral infection.
    Int J Cancer. 2024;155:1544-1548.
    >> Share

  53. LOUVANTO K, Verhoef L, Pimenoff V, Eriksson T, et al
    Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesions.
    Int J Cancer. 2024;155:1549-1557.
    >> Share

    October 2024
  54. MISHRA GA, Pimple SA, Anand KV, Kulkarni VY, et al
    Acceptability and validity of HPV self-sampling for cervical cancer screening among women living in different ecological settings in India.
    Int J Cancer. 2024 Oct 16. doi: 10.1002/ijc.35222.
    >> Share

    September 2024
  55. DEBEAUDRAP P, Kabore FN, Setha L, Tegbe J, et al
    Performance of visual inspection, partial genotyping, and their combination for the triage of women living with HIV who are screen positive for human papillomavirus: Results from the AIMA-CC ANRS 12375 multicentric screening study.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35190.
    >> Share

  56. OSTRBENK VALENCAK A, Kroon KR, Fabjan D, Mlakar J, et al
    Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: A 9-year follow-up of a population-based screening cohort.
    Int J Cancer. 2024 Sep 24. doi: 10.1002/ijc.35200.
    >> Share

  57. JERJES W
    Comments on "Epidemiological trends and survival of oropharyngeal cancer in a high HPV-prevalent area: A Danish population-based study from 2000 to 2020".
    Int J Cancer. 2024 Sep 6. doi: 10.1002/ijc.35178.
    >> Share

  58. VON BUCHWALD C, Lauritzen BB, Carlander AF, Jakobsen KK, et al
    Response to: Comments on "Epidemiological trends and survival of oropharyngeal cancer in a high HPV-prevalent area: A Danish population-based study from 2000 to 2020".
    Int J Cancer. 2024 Sep 6. doi: 10.1002/ijc.35177.
    >> Share

  59. FUJITA M, Nagashima K, Shimazu M, Suzuki M, et al
    Effectiveness of self-sampling human papillomavirus test on precancer detection and screening uptake in Japan: The ACCESS randomized controlled trial.
    Int J Cancer. 2024;155:905-915.
    >> Share

    July 2024
  60. LAURITZEN BB, Gronlund MW, Jakobsen KK, Justesen MM, et al
    Epidemiological trends and survival of oropharyngeal cancer in a high HPV-prevalent area: A Danish population-based study from 2000 to 2020.
    Int J Cancer. 2024 Jul 17. doi: 10.1002/ijc.35099.
    >> Share

  61. GILHAM C, Nedjai B, Scibior-Bentkowska D, Reuter C, et al
    Long-term prediction by DNA methylation of high-grade cervical intraepithelial neoplasia: Results of the ARTISTIC cohort.
    Int J Cancer. 2024;155:81-92.
    >> Share

    May 2024
  62. HANSEN BT, Nygard M, Castle PE, Burger EA, et al
    Sociodemographic characteristics associated with cervical cancer screening participation by send-to-all and opt-in HPV self-sampling: Who benefits? Results from a randomized controlled trial among long-term non-attending women in Norway.
    Int J Cancer. 2024 May 15. doi: 10.1002/ijc.34989.
    >> Share

    April 2024
  63. DOWNHAM L, Rol ML, Forestier M, Romero P, et al
    Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34953.
    >> Share

  64. SINGINI MG, Muchengeti M, Sitas F, Chen WC, et al
    Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34919.
    >> Share

    March 2024
  65. PORTNOY A, Pedersen K, Sy S, Trope A, et al
    Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis.
    Int J Cancer. 2024;154:1073-1081.
    >> Share

  66. OLTHOF EMG, Aitken CA, Siebers AG, van Kemenade FJ, et al
    The impact of loss to follow-up in the Dutch organised HPV-based cervical cancer screening programme.
    Int J Cancer. 2024 Mar 4. doi: 10.1002/ijc.34902.
    >> Share

  67. LU Y, Clifford GM, Fairley CK, Grulich AE, et al
    Human papillomavirus and p16(INK4a) in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis.
    Int J Cancer. 2024;154:830-841.
    >> Share

    February 2024
  68. LINDQUIST S, Frederiksen K, Petersen LK, Kjaer SK, et al
    The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
    Int J Cancer. 2024 Feb 28. doi: 10.1002/ijc.34896.
    >> Share

  69. WEN TM, Xu XQ, Zhao XL, Pan CH, et al
    Efficacy and immunogenicity of AS04-HPV-16/18 vaccine in females with existing cervical HR-HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide.
    Int J Cancer. 2024 Feb 17. doi: 10.1002/ijc.34882.
    >> Share

    January 2024
  70. STIER EA, Clarke MA, Deshmukh AA, Wentzensen N, et al
    International Anal Neoplasia Society's consensus guidelines for anal cancer screening.
    Int J Cancer. 2024 Jan 31. doi: 10.1002/ijc.34850.
    >> Share

    November 2023

  71. Correction to "A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers".
    Int J Cancer. 2023 Nov 19. doi: 10.1002/ijc.34789.
    >> Share

  72. BONI SP, Tenet V, Horo A, Heideman DAM, et al
    High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Cote d'Ivoire, 2018 to 2020.
    Int J Cancer. 2023 Nov 9. doi: 10.1002/ijc.34774.
    >> Share

    October 2023
  73. COCUZZA CE, Dhillon SK, Martinelli M, Giubbi C, et al
    Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34754.
    >> Share

    September 2023
  74. INTURRISI F, de Sanjose S, Desai KT, Dagnall C, et al
    A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study.
    Int J Cancer. 2023 Sep 29. doi: 10.1002/ijc.34698.
    >> Share

  75. LEHTINEN M, Butt J, Gray P, Brenner N, et al
    HPV16 E6-antibody associated risk of oropharyngeal cancer increases by calendar-time: A nested case-control study.
    Int J Cancer. 2023;153:1313-1315.
    >> Share

  76. KUSTERS JMA, Diergaarde B, Ness A, Schim van der Loeff MF, et al
    Diagnostic accuracy of HPV16 early antigen serology for HPV-driven oropharyngeal cancer is independent of age and sex.
    Int J Cancer. 2023 Sep 11. doi: 10.1002/ijc.34710.
    >> Share

  77. DHOKOTERA TG, Muchengeti M, Davidovic M, Rohner E, et al
    Gynaecologic and breast cancers in women living with HIV in South Africa: A record linkage study.
    Int J Cancer. 2023 Sep 8. doi: 10.1002/ijc.34712.
    >> Share

    August 2023
  78. WHITE C, Reynolds S, Murphy K, Keegan H, et al
    Performance of the HPV E6/E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland.
    Int J Cancer. 2023 Aug 26. doi: 10.1002/ijc.34685.
    >> Share

  79. VOSS FO, Thuijs NB, Duin S, Ozer M, et al
    Clinical validation of methylation biomarkers for optimal detection of high-grade vulvar intraepithelial neoplasia.
    Int J Cancer. 2023;153:783-791.
    >> Share

    July 2023
  80. KIM MN, Han K, Yoo J, Hwang SG, et al
    Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
    Int J Cancer. 2023 Jul 13. doi: 10.1002/ijc.34637.
    >> Share

  81. CLARKE MA, Wentzensen N
    Response to comments on: "A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups".
    Int J Cancer. 2023 Jul 4. doi: 10.1002/ijc.34642.
    >> Share

  82. DIAS GONCALVES LIMA F, Schim van der Loeff M
    Comments on: "A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups".
    Int J Cancer. 2023 Jul 4. doi: 10.1002/ijc.34641.
    >> Share

  83. REBOLJ M, Sargent A, Njor SH, Cuschieri K, et al
    Widening the offer of human papillomavirus self-sampling to all women eligible for cervical screening: Make haste slowly.
    Int J Cancer. 2023;153:8-19.
    >> Share

    May 2023

  84. Erratum to "A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups".
    Int J Cancer. 2023 May 19. doi: 10.1002/ijc.34567.
    >> Share

    March 2023
  85. CUZICK J, Adcock R, Kinney W, Castle PE, et al
    Impact of HPV testing in Opportunistic Cervical Screening: Support for Primary HPV Screening in the United States.
    Int J Cancer. 2023 Mar 22. doi: 10.1002/ijc.34519.
    >> Share

  86. DE SOUZA MMA, Hartel G, Olsen CM, Whiteman DC, et al
    Oral HPV infection and HPV vaccination in an Australian cohort.
    Int J Cancer. 2023 Mar 21. doi: 10.1002/ijc.34517.
    >> Share

  87. ALBUQUERQUE A
    Comments on "Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: A worldwide analysis": Prevention of anal squamous cell carcinoma in women: How to move forward: Prevention of anal squamous c
    Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34490.
    >> Share

  88. DONG L, Nygard M, Stoer NC, Klungsoyr O, et al
    Real-World Effectiveness of Hpv Vaccination Against Cervical Neoplasia Among Birth Cohorts Ineligible for Routine Vaccination.
    Int J Cancer. 2023 Mar 3. doi: 10.1002/ijc.34489.
    >> Share

    January 2023
  89. CARVAJAL LJ, Shing JZ, Vanegas JC, Gonzalez E, et al
    TRENDS IN INCIDENCE RATES OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS OVERALL AND BY POTENTIAL RELATEDNESS TO HUMAN PAPILLOMAVIRUS, COSTA RICA 2006-2015.
    Int J Cancer. 2023 Jan 17. doi: 10.1002/ijc.34437.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016